Reducing uric acid as a means to prevent cardiovascular and renal disease

Bibliography

• WU X, MUZNY DM, LEE CC, CASKEY CT: Two independent mutational events in the loss of urate oxidase during hominoid evolution. j Mal Eva (1992) 34:78–84.
   PubMed Web of Science ®Google Scholar
• CAMERON JS, MORO F, SIMMONDS HA: Uric acid and the kidney: In: The Oxford Textbook of Clinical Nephrology A, Cameron JS, Grünfeld J-P Kerr DS, Ritz E, Winearis CG (Eds), Oxford Medical Publications, Oxford, UK (1998).
   Google Scholar
• HALL AP, BARRY PE, DAWBER TR, MCNAMARA PM: Epidemiology of gout and hyperuricemia. Am. j Med. (1967) 42:27–37.
   PubMed Web of Science ®Google Scholar
• LIANG MH, FRIES JF: Asymptomatic hyperuricemia: the case for conservative management. Ann. Intern. Med. (1978) 88:666–670.
   PubMed Web of Science ®Google Scholar
• DUFFY WB, SENNEKJIAN HO, KNIGHT TF, WEINMAN EJ: Management of asymptomatic hyperuricemia. JAMA (1981) 246:2215–2216.
   PubMedGoogle Scholar
• FANG J, ALDERMAN MH: Serum uric acid acid and cardiovascular mortality. The NHANES I epidemiologic follow-up study, 1971–1992. JAMA (2000) 283:2404–2410.
   Google Scholar
• •Epidemiological evidence that uric acid is associated with cardiovascular disease.
   Google Scholar
• ALDERMAN MH, COHEN H, S, KIVLIGHN S: Serum acid and cardiovascular events in successfully treated hypertensive patients. Hypertension (1999) 34:144–150.
   PubMed Web of Science ®Google Scholar
• •Epidemiological evidence that uric acid is associated with cardiovascular disease.
   Google Scholar
• VERDECCHIA P, SCHILLLACI G, GP, SANTEUSANIO F, PORCELLATI C, BRUNETTI P: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA Study. Hypertension (2000) 36:1072–1078.
   PubMed Web of Science ®Google Scholar
• •Epidemiological evidence that uric acid is associated with cardiovascular disease.
   Google Scholar
• SELBY JV, FRIEDMAN GD, QUESENBERRY CP: Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am. j Epidemiol. (1990) 131:1017–1027.
   PubMed Web of Science ®Google Scholar
• JOSSA F, FARINARO E, PANICO S et al: Serum uric acid and hypertension: the Olivetti heart study. I Hum. Hyperteris. (1994) 8:677–681.
   PubMed Web of Science ®Google Scholar
• CANNON PJ, STASON WB, DEMARTINI FE, SOMMERS SC, LARAGH JH: Hyperuricemia in primary and renal hypertension. N Engl. I Med. (1966) 275:457–464.
   PubMed Web of Science ®Google Scholar
• TALBOTT JH, TERPLAN KL: The Kidney in Gout. (1960) Medicine 39:405–467.
   Google Scholar
• SYRJANEN J, MUSTONEN J, A: Hypertriglyceridemia and hyperuricemia are risk factors for progression of IgA nephropathy. Nephrol Dial. Transpl. (2000) 15:34–42.
   PubMedGoogle Scholar
• OHNO I, HOSOYA T, GOMI H, ICHIDA K, OKABE H, HIKITA M: Serum acid and renal prognosis in IgA nephropathy. Nephron (2001) 87:333–339.
   PubMed Web of Science ®Google Scholar
• WANNAMETHEE SG: Is serum uric acid a risk factor for coronary heart disease? Hum. Hyperteris. (1999) 13:153–156.
   Google Scholar
• VACCARINO V, KRUNHOLZ HM: Risk factors for cardiovascular disease: one down, many more to evaluate. Ann. Irm Med. (1999) 131:62–63.
   PubMed Web of Science ®Google Scholar
• JOHNSON RJ, TUTTLE K: Much ado about nothing, or much to do about something: the continuing controversy on the role of uric acid in cardiovascular disease. Hypertension (2000) 35:E10.
   Google Scholar
• MAZZALI M, HUGHES J, KIM YG et al: Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism. Hypertension (2001) 38:1101–1106.
   PubMed Web of Science ®Google Scholar
• ••Evidence that experimental hyperuricemiain rats causes hypertension, vascular and renal disease.
   Google Scholar
• MAZZALI M, KANELLIS J, HAN L et al: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. j Physiol (In Press).
   Google Scholar
• ••Evidence that experimental hyperuricemiain rats causes hypertension, vascular and renal disease.
   Google Scholar
• MAZZALI M, KIM Y-G, SUGA S et al: Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation (2001) 71:900–905.
   PubMedGoogle Scholar
• DAY RO, BIRKETT DJ, JICKS M, MINERS JO, GRAHAM GG, BROOKS PM: New uses of allopurinol. Drugs (1994) 48:339–344.
   PubMed Web of Science ®Google Scholar
• JOHNSON WD, KAYSER KL, JB, SAEDI SF: A randomized controlled trial of allopurinol in coronary bypass surgery. Am. Heart. I (1991) 121:20–24.
   PubMed Web of Science ®Google Scholar
• RASHID MA, WILLIAM-OLSSON G: Influence of allopurinol on cardiac complications in open heart operations. Ann. Thorac. &mg. (1991) 52:127–130.
   PubMed Web of Science ®Google Scholar
• TABAYASHI K, SUZUKI Y, NAGAMINE S, ITO Y, SEKINO Y, MOHRI H: A clinical trial of allopurinol (Zyloric) for myocardial protection. I Thorac. Cardiovas. &mg. (1991) 101:713–718.
   PubMed Web of Science ®Google Scholar
• COGHLAN JG, FLITTER WD, CLUTTON SM etal.: Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. I Thorac. Cardiovas. &mg. (1994) 107:248–56.
   Google Scholar
• BUTLER R, MORRIS AD, BELCH JJF, HILL A, STRUTHERS AD: Allopurinol normalizes endothelial dysfunction in Type 2 diabetics with mild hypertension. Hypertension (2000) 35:746–751.
   PubMed Web of Science ®Google Scholar
• JOHNSON RJ, KIVLIGHN SD, KIM Y-G, SUGA S, FOGO AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease Am. 1. Kid. Dis. (1999) 33:225–234.
   Google Scholar
• ROSENFELD JB: Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects. Adv. Exp. Med. Biol. (1974) 41B:581–586.
   Google Scholar
• BRINEY WG, OGDEN D, B, SMYTH CJ: The influence of allopurinol on renal function in gout. Arthritis Rheum. (1975) 18:877–881.
   PubMedGoogle Scholar
• PEREZ-RUIZ E ALONSO-RUIZ A, CALABOZO M: Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann. Rheum. Dis. (1998) 57:545–549.
   Google Scholar
• PEREZ-RUIZ E CALABOZO M, FERNANDEZ-LOPEZ MJ et al: Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled study. I Chi]. Rheumatol (1999) 5:49–55.
   Google Scholar
• PEREZ-RUIZ F, CALABOZO M, HERRERO-BEITES AM, GARCIA-ERAUSKIN G, PIJOAN JI: Improvement of renal function in patients with chronic gout after proper control of hyperuricemia gouty bouts. Nephron (2000) 86:287–291.
   PubMed Web of Science ®Google Scholar
• ARELLANO F, SACRISTAN JA: Allopurinol hypersensitivity syndrome: A review. Annals. Pharmacol (1993) 27:337–343.
   PubMed Web of Science ®Google Scholar
• EMMERSON BT: Drug therapy: the Management of Gout. N Engl. I Med. (1996) 334:445–451.
   PubMed Web of Science ®Google Scholar
• SORENSEN LB, LEVINSON DJ: Clinical evaluation of benzbromarone. A new uricosuric drug. Al-thrills. Rheum. (2001) 19:183–190.
   Google Scholar
• MASBERNARD A, GIUDICELLI CP: Ten years experience with benzbromarone in the management of gout and hyperuricaemia. S. Afi-. Med. 1 (1980) 59:701–706.
   Google Scholar
• WAGAYAMA H, SHIRAKI K, SUGIMOTO K: Fatal fulminant hepatic failure associated with benzbromarone. I Hepatol (2000) 32:874.
   Google Scholar
• NAKASHIMA M, UEMATSU T, KOSUGE K, KANAMARU M: Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur. I CBI]. Pharmacol. (1992) 42:333–335.
   Google Scholar
• •Evidence that losartan is an effective uricosuric agent.
   Google Scholar
• BURNIER M, ROCH-RAMEL F, BRUNNER HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. (1996) 49:1787–1790.
   PubMed Web of Science ®Google Scholar
• ROCH-RAMEL F, GUISAN B, DIEZI J: Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. I Pharmacol Exp. Ther. (1997) 280:839–845.
   PubMed Web of Science ®Google Scholar
• MINGHELLI G, SEYDOUX C, GOY J-J, BURNIER M: Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation (1998) 66:268–271.
   PubMed Web of Science ®Google Scholar
• TIKKANEN I, OMVIK E JENSEN HA: Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. I Hyperteris. (1995) 13:1343–1351.
   PubMed Web of Science ®Google Scholar
• GANSEVOORT RT, DE ZEEUW D, SHAHNIFAR S, REDFIELD A, DE JONG PE: Effect of the angiotensin II antagonist losartan in hypertensive patients with renal disease. I Hyperteris. (1994) 12:S37–42.
   Google Scholar
• SOFFERT BA, WRIGHT JT, PRATT H,WIENS B, GOLDBERG Al, SWEET CS: Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension (1995) 26:112–117.
   PubMedGoogle Scholar
• SHAHINFAR S, SIMPSON RL, CARIDES AD et al.: Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Lai (1999) 56:1879–1885.
   PubMed Web of Science ®Google Scholar
• LONDON M, HUDSON PB: Uricolyticactivity of purified uricase in two human beings. Science (1957) 125:937–938.
   PubMedGoogle Scholar
• MASERA G, JANKOVIC M, ZURIO MG et al: Urate oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. I PedMtr. (1982) 100:152–155.
   Google Scholar
• MASERA G, JANKOVIC M: Tumor lysis syndrome, case report and review of the literature (letter) Ann. Oricol. (1996) 8:407.
   Google Scholar
• PUI C-H, REILING MV, LASCOMBES F: Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia (1997) 11:1813–1816.
   PubMedGoogle Scholar
• PUI C-H, MAHMOUD HH, WILEY JM: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. I CBI]. Oricol. (2001) 19:697–704.
   PubMedGoogle Scholar
• •The use of uricase to treat hyperuricemia associated with malignancies is described.
   Google Scholar
• CHEN RH-L, ABUCHOWSKI A, VAN ES T, PALCZUK NC, DAVIS FF: Properties of two urate oxidases modified by covalent attachment of poly(ehtyleneglycol). Biochim. Biophys. Acta (1981) 660:293–298.
   PubMedGoogle Scholar
• DAVIS S, PARK YK, ABUCHOWSKI A, DAVIS FF: Hypouricaemic effect of polyethylene glycol modified urate oxidase. Lancet (1981) 281–283.
   PubMedGoogle Scholar
• TSUJI J-I, HIROSE K: Studies on antigenicity of the polyethylene glycol (PEG) modified uricase. mt. I Irnmurropharmacol. (1985) 7:725–730.
   PubMedGoogle Scholar
• CHUA CC, GREENBERG ML, VIAU AT, NUCCI M, BRENCKMAN WD, HERSHFIELD MS: Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann. Intern. Med. (1988) 109:114–117.
   PubMedGoogle Scholar
• Phoenix Investigator Brochure, 2001.
   Google Scholar
• KELLY SJ, DELNOMDEDIEU M, OLIVERIO MI et al: Diabetes insipidus in-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. jAm. Soc. Nephrol. (2001) 12:1001–1009.
   PubMed Web of Science ®Google Scholar
• BRAY GA, BLACKBURN GL, FERGUSON JM etal.: Sibutramine produces dose-related weight loss. Obes. Res. (1999) 7:189–198.
   Google Scholar
• JAMES WE ASTRUP A, FINER N et al.:Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet (2000) 356:2119–2125.
   Google Scholar
• MCMAHON FG, FUJIOKA K, SINGH B et al: Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch. Int. Med. (2000) 160:2185–2191.
   PubMed Web of Science ®Google Scholar
• SOOD V, COLLERAN K, BURGE MR: Thiazolidinediones: a comparative review of approved uses. Diabetes 7echnol. Ther. (2000) 2:429–440.
   Google Scholar
• IWATANI M, WASADA T, KATSUMORI, WATANABE-TAKAHASHI C, KAMATANI N, IWAMOTO Y: Troglitazone decreases serum uric acid concentrations in Type II diabetic patients and non-patients. Diabetologia (2000) 43:814–815.
   PubMed Web of Science ®Google Scholar
• GRAHAM DJ, DRINKARD CR, SHATIN D, TSONG Y, BURGESS MJ: Liver enzyme monitoring in patients treated with troglitazone. JAMA (2001) 286:831–833.
   PubMed Web of Science ®Google Scholar
• WERNER AL, TRAVAGLINI MT: A review of rosiglitazone in Type 2 diabetes mellitus. Pharmacoptherapy (2001) 21:1082–1099.
   PubMed Web of Science ®Google Scholar
• INSKEEP PB, RONFIELD RA, PETERSON MJ, GERBER N: Pharmacokinetics of the aldose reductase inhibitor, zopolrestat, in humans. j Clin. Pharmacy]. (1994) 34:760–766.
   PubMed Web of Science ®Google Scholar